K Stromer
Overview
Explore the profile of K Stromer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
246
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kirsten N, Augustin M, Stromer K
Hautarzt
. 2022 May;
73(6):501.
PMID: 35606531
No abstract available.
2.
Kirsten N, Augustin M, Stromer K
Hautarzt
. 2022 Apr;
73(5):391-397.
PMID: 35471235
Digital health applications represent a new form of care. The basis for the approval of digital health applications is the Digital Healthcare Act. In order to be included in the...
3.
Langenbruch A, Mohr N, Kirsten N, Reich K, von Kiedrowski R, Stromer K, et al.
J Eur Acad Dermatol Venereol
. 2021 Mar;
35(7):1536-1542.
PMID: 33714231
Background: In the study series PsoHealth first data from 2004/05 showed a poor quality of health care for psoriasis in Germany. Most patients lacked sufficient care and only a minor...
4.
Nast A, Smith C, Spuls P, Avila Valle G, Bata-Csorgo Z, Boonen H, et al.
J Eur Acad Dermatol Venereol
. 2021 Feb;
35(2):281-317.
PMID: 33547728
This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance...
5.
Nast A, Smith C, Spuls P, Avila Valle G, Bata-Csorgo Z, Boonen H, et al.
J Eur Acad Dermatol Venereol
. 2020 Dec;
34(11):2461-2498.
PMID: 33349983
This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The first part of the guideline includes general...
6.
Zander N, Krensel M, Schafer I, Weyergraf A, Mohr P, Stromer K, et al.
Hautarzt
. 2019 Jul;
70(10):804-810.
PMID: 31267179
Background: Treatment of patients with malignant melanoma includes informing the patients about their rights regarding social/disability benefits. In particular, every patient has the right to rehabilitation treatment according to SGB ...
7.
Philipp-Dormston W, Muller K, Novak B, Stromer K, Termeer C, Hammann U, et al.
J Eur Acad Dermatol Venereol
. 2017 Nov;
32(7):1138-1146.
PMID: 29150868
Background: Non-melanoma skin cancer (NMSC) and actinic keratosis (AK) are very common among fair-skinned individuals. A disease continuum from AK to squamous cell carcinoma (SCC) has been frequently postulated. AK...
8.
Jungen D, Augustin M, Langenbruch A, Zander N, Reich K, Stromer K, et al.
J Eur Acad Dermatol Venereol
. 2017 Sep;
32(1):174-180.
PMID: 28857297
Background: Though psoriasis poses a substantial chronic socio-economic burden, few studies have addressed the economic impact in Germany. Objectives: The objective was to evaluate the annual costs of psoriasis in...
9.
Augustin M, Eissing L, Elsner P, Stromer K, Schafer I, Enk A, et al.
J Eur Acad Dermatol Venereol
. 2017 Jul;
31(12):2124-2130.
PMID: 28707710
Background: In contrast to other European countries, dermatologists in Germany provide health care for a broad spectrum of diseases of the skin and mucous membranes. Current population-based data on the...
10.
Eissing L, Schafer I, Stromer K, Kaufmann R, Enk A, Reusch M, et al.
Hautarzt
. 2017 Mar;
68(5):371-376.
PMID: 28246676
Background: Since 2008, German statutory health insurances offer routine skin cancer screening (rSCS) as a standard benefit. Insured persons aged 35 years and older are eligible for screening every 2 ...